Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_assertion type Assertion NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_head.
- NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_assertion description "[To examine the relevant regulation of PCAN1, pGL(3)-p2.6 kb was transfected into the prostate cancer cell line LNCaP, which was treated with R1881 (10(-7) approximately 10(-9) mol/l), 17beta-estradiol (17beta-E(2), 10(-7) approximately 10(-9) mol/l), all-trans-retinoic acid (all-trans-RA, 10(-5) approximately 10(-7) mol/l) or 9-cis-retinoic acid (9-cis-RA, 10(-5) approximately 10(-7) mol/l), and eukaryotic expression plasmids of NKX3.1, p53, Sp1, Pten, PPARgamma or cEBPalpha were cotransfected with pGL(3)-p2.6 kb into LNCaP cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_provenance.
- NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_assertion evidence source_evidence_literature NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_provenance.
- NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_assertion SIO_000772 17468839 NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_provenance.
- NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_assertion wasDerivedFrom befree-2016 NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_provenance.
- NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_assertion wasGeneratedBy ECO_0000203 NP607364.RAVr-f8V0aIbk8puAlrLS_uO8nz5S2ixY1OjW6Y_fZ6Nw130_provenance.